CTLA-4 antibody ipilimumab negatively affects CD4(+) T-cell responses in vitro

Immune checkpoint inhibitors targeting coinhibitory pathways in T cells possess efficacy in combating cancer. In addition to PD-1/PD-L1 and CTLA-4 antibodies which are already established in tumor immunotherapy, immune checkpoints such as LAG-3 or BTLA are emerging, which may have the potential to e...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosskopf, Sandra, Leitner, Judith, Zlabinger, Gerhard J., Steinberger, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683241/
https://www.ncbi.nlm.nih.gov/pubmed/31332464
http://dx.doi.org/10.1007/s00262-019-02369-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683241/
https://www.ncbi.nlm.nih.gov/pubmed/31332464
http://dx.doi.org/10.1007/s00262-019-02369-x

Ejemplares similares